Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Decline in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,200 shares, a decrease of 63.6% from the January 15th total of 19,800 shares. Based on an average daily volume of 841,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.7% of the company’s stock are short sold.

Avalon GloboCare Stock Down 2.6 %

Shares of NASDAQ ALBT traded down $0.10 during trading on Friday, reaching $3.63. 2,326 shares of the company traded hands, compared to its average volume of 29,911. The firm has a 50 day simple moving average of $3.62 and a 200-day simple moving average of $3.62. The stock has a market capitalization of $3.95 million, a PE ratio of -0.18 and a beta of 0.19. Avalon GloboCare has a 52-week low of $2.11 and a 52-week high of $21.60.

Avalon GloboCare (NASDAQ:ALBT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.82) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.